Image

Study Evaluating Near-infrared Imaging Coupled With Indocyanine Green for Intraoperative Control of Resection Margins in ENT Surgery

Recruiting
18 years of age
Both
Phase 2

Powered by AI

Overview

Assess the sensitivity of real-time near-infrared fluorescence imaging to detect microscopic residual disease in the operating room after a complete macroscopic surgical resection of head and neck cancers

Eligibility

Inclusion Criteria:

  • Male or female 18 years of age or older
  • ECOG performance status 0-2
  • Histological confirmation of squamous cell carcinoma
  • Locating the primary tumour in the oral cavity or oropharynx
  • Disease operable for complete resection
  • Serum or urinary pregnancy test (as per centre practices) negative within 14 days prior to systemic indocyanin green injection (pre-operative visit), for women of childbearing age
  • Patient information and signed free and informed consent
  • Patient affiliated with a social security scheme or beneficiary of a similar scheme.
  • The patient must understand, sign and date the consent form prior to any protocol-specific procedures. The patient must be able and willing to comply with the study visits and procedures described in the protocol

Exclusion Criteria:

  • Severe medical co-morbidities or contraindications to surgery
  • Primary tumour not operable
  • History of head and neck cancer in the past 5 years
  • History of radiation for head and neck cancer
  • Metastatic cancer
  • Tumours with necrosis ranges in pre-operative imaging
  • History of invasive cancer unless there has been no recurrence for more than 5 years with an exception for non-melanoma skin cancers.
  • Pregnant or nursing woman
  • Allergy or hypersensitivity to the product being administered (its active substance or other ingredients), iodized products or crustaceans.
  • Hyperthyroidism, thyroid adenoma, unifocal, multifocal or multinodular goiter of autoimmune origin.
  • Documented coronary artery disease
  • Advanced renal failure (creatinine > 1.5mg/dL).
  • Within 2 weeks prior to inclusion, concomitant medication that reduces or increases extinction of GI (i.e. anticonvulsants, haloperidol and Heparin).
  • Patient under guardianship or curatorship or deprived of liberty by judicial or administrative decision or patient unable to give consent.
  • Patients unable to undergo medical follow-up of the trial

Study details

Head and Neck Cancer

NCT04842162

Gustave Roussy, Cancer Campus, Grand Paris

26 May 2024

Step 1 Get in touch with the nearest study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.